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The aims of this study were to assess changes in quality of life (QoL) scores in relation to radical radiotherapy for gynaecological
cancer (before and after treatment up to 3 years), and to identify the effect that late treatment effects have on QoL. This was a
prospective study involving 225 gynaecological cancer patients. A QoL instrument (European Organisation for the Research and
Treatment of Cancer QLQ-C30) and late treatment effect questionnaire (Late Effects Normal Tissues – Subjective Objective
Management Analysis) were completed before and after treatment (immediately after radiotherapy, 6 weeks, 12, 24 and 36 months
after treatment). Most patients had acute physical symptoms and impaired functioning immediately after treatment. Levels of fatigue
and diarrhoea only returned to those at pre-treatment assessment after 6 weeks. Patients with high treatment toxicity scores had
lower global QoL scores. In conclusion, treatment with radiotherapy for gynaecological cancer has a negative effect on QoL, most
apparent immediately after treatment. Certain late treatment effects have a negative effect on QoL for at least 2 years after
radiotherapy. These treatment effects are centred on symptoms relating to the rectum and bowel, for example, diarrhoea, tenesmus
and urgency. Future research will identify specific symptoms resulting from late treatment toxicity that have the greatest effect on
QoL; therefore allowing effective management plans to be developed to reduce these symptoms and improve QoL in gynaecological
cancer patients.
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An increase in survival rates over the last few decades (Cancer
Research UK, 2006) has lead to a greater proportion of patients
living with the late adverse effects of cancer treatment. The effect of
these long-term problems on a patient’s physical, social and
psychological well-being needs to be addressed in oncology
research and practice.
Around one in ten women in the UK living with a diagnosis of
cancer will have a gynaecological malignancy (Forman et al, 2003).
There are particular challenges in addressing the long-term needs
of gynaecological cancer survivors. Patients report more gastro-
intestinal symptoms and sexual dysfunction than women in the
general population, even several years after therapy (Bergmark
et al, 1999; Bye et al, 2000; Klee and Machin, 2001). In addition,
treatment is associated with a loss of fertility and the use of long-
term hormone replacement therapy to control menopausal
symptoms.
Surgery, radiotherapy and chemotherapy are effective treatment
options for patients with gynaecological cancers, and these are
increasingly being used in combination to improve survival (Green
et al, 2001; Ryn et al, 2005). The use of multimodal treatment
regimes is associated with a rise in the incidence of late treatment
effects seen within the pelvis (Landoni et al, 1997; Creutzberg et al,
2000). These are defined as toxicity present at least 3 months after
the completion of radiotherapy (Maher and Denton, 2008). Despite
an increasing trend in using multimodal treatment regimes in
oncology practice, there are a paucity of data on long-term
treatment effects (Kirwan et al, 2003) and their subsequent effect
on quality of life (QoL) in gynaecological cancer patients.
Health-related QoL is a subjective patient estimation regarding
the effect of disease and treatment variables on the outcomes of
emotional, social, physical and functioning well-being. There are
many interactions between symptoms, functional status and
overall QoL (Osoba, 2007), and it cannot be linked in a straight-
forward way to a particular degree of organ or tissue damage
(Maher and Denton). There are several studies in the literature that
explain the physical, psychological and social effects of gynaecolo-
gical cancer and its treatment (presented in Table 1). Many of these
studies are prospective and they describe the initial decrements in
QoL immediately after therapy. However, the length of time before
complete recovery is unclear, with the longest prospective study
showing that QoL never reached that of healthy controls after a 24-
m o n t hp e r i o d( K l e eet al, 2000a). Crucially these studies do not take
into account the symptoms experienced from late treatment effects,
which typically manifest around 2–3 years after treatment (Denton
et al, 2000), and their consequent effect on QoL.
It is important to measure QoL and late treatment effects
accurately in order to identify, and therefore effectively manage
those symptoms causing the greatest distress after treatment.
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sInstruments measuring QoL should be reliable, valid and
responsive to changes over time (Cella et al, 2002). They should
also take a ‘multidimensional’ approach that involves assessing
physical, functional, social and emotional well-being. Many of the
more commonly used and well-validated questionnaires include
domains in these areas. In addition, they have site-specific
modules that can be used wherever relevant.
In contrast, there is no general consensus on the best way to
quantify normal tissue damage and to record treatment-related
effects (Bentzen et al, 2003). Reports of the frequency of late
treatment effects from pelvic radiotherapy vary, and this may
reflect the different techniques used to score treatment-related
toxicity (Hoeller et al, 2003). This variation may also be because of
a lack of documentation of these effects, especially those deemed
less serious by health professionals (Davidson et al, 2003). The
Late Effects Normal Tissues (LENT) – Subjective Objective
Management Analysis (SOMA) scoring system (LENT SOMA
tables, 1995) addresses both the patient’s view on their symptoms
and a clinician’s opinion on morbidity, and therefore provides a
comprehensive measure of late treatment effects. These LENT
SOMA items have subsequently been incorporated into the
National Cancer Institute’s (NCI) Common Terminology Criteria
for Adverse Events (CTCAE), which includes a comprehensive
catalogue of potential normal tissue effects.
There were two main objectives of this QoL study. The first was
to examine the QoL of women undergoing radiotherapy for
treatment of gynaecological cancer (before and after treatment up
to 3 years using European Organisation for the Research and
Treatment of Cancer (EORTC) QLQ-C30 (Aaronson et al, 1993))
prospectively. The second aim was to identify the effect of late
treatment effects assessed using the LENT SOMA scales on the QoL
of these patients.
MATERIALS AND METHODS
The gynaecological cancer patients that were approached to take
part in the study (between 1998 and 2006) were only those
patients that were to receive radical radiotherapy treatment
(radiotherapy with curative intent). A total of 225 patients were
recruited prospectively at the Christie Hospital, Manchester.
Patients were asked to complete questionnaires either by interview
with a research nurse or self-administered at home and returned
by post.
Table 1 Earlier research on the QoL in gynaecological cancer patients
Author Study design Cancer Number QoL instrument Results
Bye et al (2000) Cross-sectional Endometrial
and cervical
79 EORTC QLQ-C36 Lower QoL in the areas of diarrhoea and role functioning than in
normal population 3–4 years after radiotherapy. Pain and diarrhoea
associated with decrease in QoL
Klee et al (2000a) Prospective cohort Cervical and
vaginal
118 EORTC QLQ-C30 Overall QoL reduced compared with a control group, even at 24
months after treatment
Klee et al (2000b) Prospective cohort Cervical 118 EORTC QLQ-C30 Acute physical symptoms up to 3 months after treatment. Frequent
voiding and diarrhoea may become chronic symptoms
Klee and Machin
(2001)
Prospective cohort Endometrial 49 EORTC QLQ-C30 Physical symptom scores were highest immediately after treatment.
Global QoL lower than healthy controls
Leake et al (2001) Cross-sectional Gynaecological 202 FLI-C Treatment with radiotherapy is associated with deterioration in
QoL scores
Greimel et al
(2002)
Prospective cohort Gynaecological
or breast
248 EORTC QLQ-C30 Decrease in global QoL, emotional functioning and role functioning
up to 1 year after treatment
Lutgendorf et al
(2002)
Prospective cohort Gynaecological 98 FACT-G, POMS Decrements in physical, functional and total well-being reported at
baseline. Improvements in QoL and mood by 1 year
Frumovitz et al
(2005)
Cross-sectional Cervical 114 SF-12, BSI-18, A-
DAS, CARES, FSFI
Patients treated with radiotherapy had a worse sexual functioning
than those treated with surgery alone
Wenzel et al
(2005)
Cross-sectional Cervical 51 SF-36, QOL-CS,
IES, GPC, SAQ,
ISEL, FACT-Sp,
COPE
QoL and functioning in cervical cancer survivors comparable with
age-matched controls. Cancer-specific distress, spiritual well-being,
maladaptive coping and reproductive concerns are predicative of
individual QoL
Bradley et al (2006) Cross-sectional Cervical and
endometrial
152 SF-36, FACT-G,
CES-D, POMS
No significant differences in QoL or depressive symptoms between
cancer survivors or healthy controls. However, cervical cancer
survivors report more negative mood
Vistad et al (2006) Critical review Cervical 2041 Self-report
measures
QoL in cervical cancer survivors is reduced compared with the
general population after radiotherapy
Vistad et al (2007) Cross-sectional Cervical 79 FQ, HADS, SF-36,
SAQ, LENT-
SOMA
Almost one-third of cervical cancer survivors report chronic fatigue
(CF). Those with CF had significantly lower QoL and higher levels
of depression, anxiety and physical impairment
Distefano et al
(2008)
Prospective cohort Cervical 93 SF-36, HADS QoL scores comparable between locally advanced cervical cancer
patients receiving pre-operative chemotherapy and those with early
stage disease. Poor QoL scores associated with anxiety disorders,
low educational level and unemployment status
Greimel et al
(2008)
Cross-sectional Cervical 121 EORTC QLQ-C30,
QLQ-CX24, SAQ
Patients treated with adjuvant radiotherapy are more likely to have
impaired QoL than those treated with surgery or adjuvant
chemotherapy
A-DAS¼Abbreviated Dyadic Adjustment Scale; BSI-18¼Brief Symptom Inventory 18; CARES¼Cancer Rehabilitation Evaluation System; CES-D¼Center for Epidemiologic
Studies Depression scale; COPE¼Coping Orientations to Problems Experienced Scale; EORTC¼European Organisation for the Research and Treatment of Cancer;
FACT-G¼Functional Assessment of Cancer Therapy (General); FACT-Sp¼Functional Assessment of Cancer Therapy-Spirituality Scale; FLI-C¼Functional Living Index;
FQ¼Fatigue Questionnaire; FSFI¼Female Sexual Function Index; GPC¼Gynecologic Problems Checklist; HADS¼Hospital and Depression Scale; IES¼Impact of Event
Scales; ISEL¼Interpersonal Support Evaluation List; LENT SOMA¼Late Effects of Normal Tissue, Subjective Objective Management Analysis; POMS¼Profile of Mood States;
QoL-CS¼Quality of Life – Cancer Survivorship; SAQ¼Sexual Activity Questionnaire; SF-12¼Short Form 12; SF-36¼Short Form 36.
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sApproval for this study was obtained from the South
Manchester Research Ethics Committee. Patients who developed
disease recurrence or had progression of the disease were excluded
from this study.
At the time of completion, patients were also asked whether they
wished to discuss any concerns they may have had in a
consultation with a doctor. They were also asked to document
any issues not related to their cancer that may influence their QoL
scores (e.g., the breakdown of a relationship may have a negative
effect on QoL).
The first questionnaire was completed before the start of
radiotherapy and served as a baseline assessment. Time periods
after treatment were measured from the last day of treatment. The
post-radiotherapy questionnaires were completed after treatment
(from 9 days before end to 12 days after completion of treatment)
at 6 weeks after radiotherapy (±2 weeks), and at 12 months (±4
weeks), 24 months (±4 weeks) and 36 months (±4 weeks). Any
questionnaires completed outside the designated range were not
included in the statistical analysis.
Sixty-one patients received radiotherapy alone for treatment of a
gynaecological malignancy. Ninety-three patients received radio-
therapy treatment after radical hysterectomy either because of
nodal involvement on histological examination or if the surgical
margins were considered unsatisfactory (when vault intra-cavity
treatment was also given). Concomitant chemoradiation (without
surgery) was used in the treatment of 42 patients and a
combination of all three treatment modalities was used for 29
patients.
The EORTC QLQ-C30 is a cancer-specific 30-item questionnaire
intended for use in clinical trials (Aaronson et al, 1993). It was
designed to be multidimensional, self-administered and acceptable
across a range of cultures. For the EORTC QLQ-C30 questionnaire,
30 question scores were transformed according to the EORTC
QLQ-C30 scoring manual (Fayers et al, 1999).
The LENT SOMA scales were originally published in 1995 and a
37-item questionnaire was produced to contain the LENT
subjective scales (Davidson et al, 2003). The latest version of this
questionnaire can be found at the Christie Hospital website
(www.christie.nhs.uk).
A programme was written to score the LENT SOMA scales
according to the criteria proposed in the 1995 published tables.
The questionnaires were divided into six subsites: uterus/cervix,
ovary/reproductive, rectum/bowel, bladder/urethra, ureter/kidney
and vagina (including questions on sexual function). Each
symptom was scored with increasing severity on a scale of 0–4;
with 4 being the highest intensity. An average score was calculated
from the questions asked about each subscale. If 450% of the
questions were missing in any one subscale or for any one person,
then the average score was defined as missing and the data were
not used. An overall LENT SOMA score was also formed for all the
questions in the questionnaire.
Statistical analysis
As the data were not normally distributed nonparametric statistics
were used. Friedman’s two-way analysis of variance was not
utilised to examine the changes in scores with time, as the sample
size was small at 36 months after treatment. Instead the Wilcoxon
matched pairs signed rank test was used and a Bonferroni
correction applied. Therefore, all changes in scores with time
(e.g., from baseline assessment to 6 weeks after treatment) are
reported at a reduced level of 0.01 significance (0.05 per number of
tests). Mann–Whitney U and Kruskal–Wallis tests were used to
analyse statistically significant differences between groups. Corre-
lations between the EORTC QLQ-C30 global QoL scale and age
were carried out by determining the Spearman’s correlation
coefficients.
RESULTS
Compliance
Of the 225 patients taking part in this research, nine did not wish
to continue taking part and 39 patients stopped returning
questionnaires during the lifetime of the study. Patients excluded
from the study included 35 patients who developed recurrence and
14 patients who died during the 3-year period. This gave a total of
176 patients, who have either completed or been withdrawn
(developed recurrence or died) from this prospective study, with
49 patients still at various time points after treatment. Complete
data regarding compliance were only available for 176 of the 225
patients; therefore, it was determined from this set of 176 patients
that the percentage that stopped returning questionnaires (i.e., 39
patients) was equal to 27.3%. This gave an overall level of
compliance of 72.7%.
Of the 225 patients taking part in this research, a total of 222
patients returned completed questionnaires at the pre-treatment
assessment and 183 patients completed the questionnaires
immediately after treatment. The total number of completed
LENT SOMA and EORTC QLQ-C30 questionnaires returned at 6
weeks after treatment was 61, at 12 months it was 83, at 24 months
it was 65 and finally at 36 months 45 patients completed the
questionnaires.
The patient characteristics are summarised in Table 2.
QoL scores over time
Figure 1 provides an illustration of QoL (EORTC QLQ-C30
subscales) throughout the course of treatment for gynaecological
cancer and the 3-year follow-up. Baseline scores provided by
assessments completed before the start of radiotherapy were
compared with subsequent QoL results.
Table 3 shows the EORTC QLQ-C30 subscale scores (mean and
median) over the study. High scores on the global QoL and
functional scales represent good QoL; therefore, an increase in
scores over time signifies an improvement in QoL. Immediately
after treatment, scores for global QoL and physical, role, cognitive
and social functioning were all decreased significantly when
compared with pre-treatment levels (P-value o0.01).
Table 2 Patient characteristics
Number of patients recruited 225
Age at the end of radiotherapy treatment (years)
Mean 54.3
Median 55.0
Range 24–85
Cancer site Number of patients Per cent (%)
Cervix 167 74.2
Endometrium 57 25.3
Vagina 1 0.5
Stage of disease
I 71 31.7
II 85 37.9
III 38 17.0
IV 16 7.1
Unknown 15 6.3
Treatment received
Radiotherapy alone 61 27.1
Radiotherapy and surgery 93 41.3
Radiotherapy and chemotherapy 42 18.7
Radiotherapy, chemotherapy and surgery 29 12.9
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QLQ-C30 signify a high level of symptom experience and therefore
poor QoL. An increase in scores over time represents a
deterioration in QoL. Immediately after treatment, symptom
scores for fatigue, nausea, loss of appetite and diarrhoea were all
significantly higher than at pre-treatment assessment. At 6 weeks
after radiotherapy, symptom scores for fatigue and diarrhoea were
still significantly increased when compared with pre-treatment
assessment.
At 12 months after the end of radiotherapy, no scores for any of
the EORTC QLQ-C30 subscales were significantly different from
those taken at pre-treatment assessment; therefore, by 1 year all
subscale scores had returned to baseline levels.
Treatment-related toxicity scores over time
Figure 2 provides an illustration of treatment-related toxicity (LENT
SOMA subscale scores) throughout the course of treatment for
gynaecological cancer and the 3-year follow-up. Baseline scores
provided by assessments completed before the start of radiotherapy
were compared with subsequent treatment-related toxicity results.
Table 4 shows LENT SOMA subscales scores (mean and median)
over the study. High scores on the subscales of the LENT SOMA
indicate high levels of symptom experience from treatment-related
toxicity. Both bowel and overall LENT SOMA scores showed
significant increases from pre-treatment assessment at all time
points after treatment (P-values o.01).
Immediately after treatment, LENT SOMA bladder/urethra and
pain scores were significantly increased when compared with pre-
treatment assessment. At 6 weeks after the end of radiotherapy,
ovary/reproductive, ureter/kidney and vagina/sexual function
scores were significantly higher. Ureter/kidney scores remained
significantly increased at all time points from 6 weeks after
radiotherapy. Conversely, uterus/cervix scores showed significant
decreases at 24 months after treatment. Finally at 36 months after
treatment, scores for bladder/urethra were significantly increased
from pre-treatment assessment.
Relationship between QoL and late treatment effects
In order to analyse the relationship between QoL and the level of
symptom experience from late treatment effects, the sample was
divided into two groups of patients according to their overall
LENT SOMA scores. These were calculated from the LENT SOMA
questionnaire completed at the same time point as the EORTC
QLQ-C30. One group included those patients with an overall LENT
SOMA score below the mean value (the ‘low’ LENT SOMA group),
with the second group consisting of those patients with a score
above the mean value (the ‘high’ LENT SOMA group).
Figure 3 shows the difference in global QoL scores between the two
groups over time. At all the time periods (except 36 months) there were
statistically significant differences between the two groups (Po0.05).
The clear trend was for global QoL scores to be significantly lower in
those patients in the high LENT SOMA score group.
The mean rank was lower in the ‘high’ LENT SOMA group than
the ‘low’ LENT SOMA group. This does show a link between high
overall LENT SOMA scores and decreased QoL at this time point.
This was not statistically significant however, and could be because
of the small number of patients included in the analysis at this time
point (n¼27).
Relationship between median global QoL score and disease
stage, treatment modality and patient age
To analyse the different stages of disease, the sample was split into
patients with earlier cancer stages (I, II) and patients with
advanced disease (III, IV). Although higher stage disease was
associated with a lower global QoL subscale score, the only
statistically significant difference between the two groups was at
the 12-month assessment (P¼0.012).
Additionally the number of different treatments each patient
received was compared with the median global QoL score at each
time point. Radiotherapy, chemotherapy and surgery were each
counted as distinct treatment types. There were no statistically
significant differences between median global QoL scores for the
number of treatment modalities received at any time point (all P-
values 40.05).
Finally the age of the patient (calculated from the end of
radiotherapy treatment) was compared with the median global
QoL score at each time point. There were no significant
correlations between age and median global QoL scores at any
point before or after radiotherapy treatment (all P-values 40.05).
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Figure 1 European Organisation for the Research and Treatment of
Cancer QLQ-C30 subscales over time (months). Higher scores on the
global quality of life (QoL) and functional scales represent better QoL,
whereas higher scores on the symptom scales correspond to a higher level
of symptom experience, and therefore worse QoL (range 0–100).
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Pre-treatment
Immediately after
treatment 6 weeks 12 months 24 months 36 months
Global QoL
Mean 67 55** 68 70 65 66
Median 75 50** 67 67 67 67
(LQ–UQ) (58–83) (33–75) (50–67) (67–83) (58–92) (50–83)
EORTC QLQ-C30 functional scales
Physical functioning
Mean 79 75* 76 81 80 81
Median 80 73* 80 87 93 93
LQ–UQ (67–93) (53–93) (67–93) (80–100) (87–100) (67–100)
Role functioning
Mean 73 55** 72 79 80 81
Median 83 67** 67 100 100 100
LQ–UQ (50–100) (0–83) (33–100) (83–100) (67–100) (67–100)
Cognitive functioning
Mean 83 76** 81 77 73 75
Median 100 83** 83 83 83 83
LQ–UQ (67–100) (33–83) (83–83) (67–83) (67–83) (67–100)
Emotional functioning
Mean 74 73 73 75 71 72
Median 75 67 67 83 67 67
LQ–UQ (67–83) (33–75) (42–75) (67–83) (58–83) (67–100)
Social functioning
Mean 77 66* 75 81 80 81
Median 83 67* 67 100 100 83
LQ–UQ (67–100) (17–100) (17–83) (83–100) (67–100) (67–100)
EORTC QLQ-C30 symptom scales
Fatigue
Mean 29 48** 36* 29 27 22
Median 22 33** 33* 11 11 11
LQ–UQ (0–22) (22–67) (0–56) (11–33) (0–22) (0–33)
Nausea
Mean 9 20** 4 8 9 9
Median 0 17** 0 0 0 0
LQ–UQ (0–17) (0–33) (0–0) (0–17) (0–17) (0–17)
Pain
Mean 20 24 18 14 18 20
Median 17 17 33 0 0 0
LQ–UQ (0–17) (0–67) (0–33) (0–17) (0–17) (0–17)
Dyspnoea
Mean 14 13 20 14 21 16
Median 0 0 0 0 0 0
LQ–UQ (0–0) (0–0) (0–33) (0–33) (0–33) (0–33)
Insomnia
Mean 35 36 37 27 32 27
Median 0 33 33 33 33 33
LQ–UQ (0–0) (0–67) (33–67) (0–33) (0–33) (0–67)
Loss of appetite
Mean 16 36** 13 9 9 12
Median 0 33** 0 0 0 0
LQ–UQ (0–33) (0–83) (0–33) (0–0) (0–0) (0–0)
Constipation
Mean 15 10 9 8 9 12
Median 0 0 0 0 0 0
LQ–UQ (0–0) (0–0) (0–0) (0–0) (0–0) (0–0)
Diarrhoea
Mean 10 47** 13* 13 14 10
Median 0 67** 0* 0 0 0
LQ–UQ (0–0) (33–100) (0–33) (0–0) (0–0) (0–0)
Financial difficulties
Mean 17 20 22 12 14 12
Median 0 0 0 0 0 0
LQ–UQ (0–0) (0–0) (0–33) (0–0) (0–0) (0–0)
EORTC¼European Organisation for the Research and Treatment of Cancer; LQ–UQ¼Lower quartile – upper quartile. *Po0.01 vs pre-treatment. **Po0.001 vs pre-
treatment.
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This longitudinal study was carried out to assess QoL scores over
time in gynaecological patients treated with radiotherapy. With an
increasing trend for using multimodal treatment regimes, and a
lack of data on long-term toxicity, this research is well placed to
identify both acute and late treatment effects and their associated
effect on QoL scores.
The results from this study showed that patients have a
high level of impairment in most of the QoL subscales immediately
after treatment. These decrements are well documented
in the literature with most prospective studies (Klee et al,
2000a,b; Klee and Machin; Greimel et al, 2002; Distefano et al,
2008) supporting a known increase in physical symptoms
and impaired level of functioning directly after radiotherapy.
On average there was a mean change score of about 5–10 on the
EORTC QLQ-C30 subscales between before and immediately
after treatment. This therefore indicates a clinically meaningful
change in QoL after radiotherapy treatment (King, 1996;
Osoba et al, 1998).
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Figure 2 Late Effects Normal Tissues (LENT) – Subjective Objective
Management Analysis (SOMA) subscales over time (months). Higher
scores on the LENT SOMA scales indicate a higher level of symptom
experience from treatment-related toxicity (range 0–4).
Table 4 LENT SOMA subscale scores at each assessment
Pre-treatment
Immediately
after-treatment 6 weeks 12 months 24 months 36 months
EORTC QLQ-C30 symptom scales
Uterus/ Cervix
Mean 0.64 0.71 0.49 0.54 0.48* 0.54
Median 0.75 0 0 0 0* 0.5
LQ–UQ 0.75–1.25 0–1.25 0–1.00 0–0.75 0–0.75 0–0.75
Ovary/Reproductive
Mean 0.67 0.71 1.12* 0.82 0.79 0.72
Median 0 0 2* 0 0 0
LQ–UQ 0–0 0–1 0–2 0–1 0–2 0–1
Rectum/ Bowel
Mean 0.19 0.53** 0.19** 0.32** 0.31** 0.29**
Median 0 0.62** 0.07** 0.21** 0.21** 0.14**
LQ–UQ 0–0.07 0.21–1.15 0–0.29 0.07–0.31 0.14–0.36 0–0.29
Bladder/ Urethra
Mean 0.49 0.66** 0.56 0.52 0.59 0.59*
Median 0.29 0.43** 0.43 0.43 0.33 0.71*
LQ–UQ 0.14–0.43 0.14–1.00 0.14–0.57 0.14–1.00 0.14–0.71 0.14–1.14
Ureter/ Kidney
Mean 0.21 0.30 0.37* 0.45* 0.45* 0.50*
Median 0 0 0* 1* 0* 1*
LQ–UQ 0–0 0–0 0–1 0–1 0–1 0–1
Vagina/sexual function
Mean 0.65 0.65 0.72* 0.65 0.68 0.66
Median 0.57 0.57 0.56* 0.57 0.57 0.67
LQ–UQ 0.50–0.57 0.57–0.57 0.43–0.67 0.30–0.67 0.33–0.71 0.50–0.80
Pain
Mean 0.48 0.71** 0.37 0.46 0.48 0.48
Median 0.25 0.5** 0.5 0.25 0 0.25
LQ–UQ 0–0.50 0–1.14 0–0.75 0–0.71 0–0.43 0–0.43
Overall LENT SOMA score
Mean 0.43 0.61** 0.46** 0.50** 0.51* 0.51*
Median 0.32 0.47** 0.38** 0.5** 0.33* 0.59*
LQ–UQ 0.18–0.38 0.44–1.00 0.29–0.68 0.29–0.66 0.30–0.53 0.29–0.63
EORTC¼European Organisation for the Research and Treatment of Cancer; LENT SOMA¼Late Effects Normal Tissues (LENT) – Subjective Objective Management Analysis;
LQ–UQ¼Lower quartile – upper quartile. *Po0.01 vs pre-treatment. **Po0.001 vs pre-treatment.
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least 6 weeks after radiotherapy. Fatigue is a known side effect of
radiotherapy (Jereczek-Fossa et al, 2002). It tends to gradually
increase during treatment and then decline over time, returning to
pre-treatment levels 1–2 months after the end of radiotherapy. The
results from this study concur with these observations. By 1 year
all of the EORTC QLQ-C30 subscale scores had returned to
pre-treatment levels. This result agrees with findings from a
prospective study conducted by Lutgendorf et al, who reported an
increase in QoL and mood in gynaecological cancer patients in the
first year after treatment.
The LENT SOMA scores showed significant increases in
treatment toxicity immediately after radiotherapy for the rectum/
bowel, bladder/urethra, pain and overall LENT SOMA scales. For
both the rectum/bowel and overall LENT SOMA scales, scores were
significantly elevated at each time point until 3 years after
radiotherapy and never reached the pre-treatment levels. These
results correspond to the findings obtained by Klee et al who
reported the trend for diarrhoea to become a chronic problem after
irradiation. Bye et al also studied gynaecological cancer survivors
3–4 years after radiotherapy treatment and found diarrhoea was a
common symptom. This study also found that scores for the
bladder/urethra scale returned to those seen at pre-treatment
assessment within 1 year after radiotherapy. However, there was a
significant increase in the average bladder/urethra scores at 3 years
after radiotherapy. These results correspond to past research on
both acute and late toxicities related to radiotherapy treatment
(Andreyev, 2007). A UK audit of gynaecological cancer patients
treated in 1993 reported that the timing of treatment-related
complications differed, with 75% of bowel toxicities occurring
within the first 18 months and 73% of bladder toxicities
documented between 2–3 years (Denton et al, 2000).
It is interesting that, although the overall LENT SOMA and
rectum/bowel scores remained significantly increased for 3 years
after radiotherapy treatment, scores for all the EORTC QLQ-C30
subscales returned to normal by 1 year. This may be because of a
phenomenon in QoL research known as ‘response shift’ (Carver
and Scheier, 2000); where patients may learn to cope with
problems and the symptoms they experience, and therefore adjust
their own internal values and standards.
In terms of treatment-related adverse effects, the global QoL
subscale showed significant differences between the ‘low’ and
‘high’ LENT SOMA score groups for 2 years after radiotherapy.
These findings imply that treatment morbidity has a negative effect
on QoL scale scores for many years after treatment. In contrast,
FIGO stage was shown to only have a statistically significant effect
on global QoL scores at 12 months after treatment, and there was
no association between either treatment modality or patient’s age
and global QoL scores.
As the rectum/bowel subscale scores were significantly raised at
all time points after radiotherapy, it can be suggested that late
treatment effects relating to this subscale have the biggest effect on
QoL. These treatment effects include symptoms such as diarrhoea,
tenesmus and urgency. Scores for the bladder/urethra became
significantly raised at 3 years after treatment, and a longer
prospective study is needed to ascertain whether late treatment
effects of the bladder negatively affect QoL after this time point.
Finally, earlier research has shown that sexual problems because of
radiotherapy treatment are experienced by women (Burns et al,
2007). Although this study does not show significant effect of
sexual function scores on QOL, more work is needed to assess the
effect of late treatment effects on sexual function.
To our knowledge no other study has compared data collected
from QoL questionnaires with site-specific scores obtained on late
effects toxicity related to gynaecological cancer treatment. There-
fore, no direct comparisons can be made with the earlier research.
In Greimel et al (2008), patients with high-stage disease were
associated with lower functioning scores on the EORTC QLQ-C30
subscales. The results obtained from this research are therefore
indirectly in agreement with these findings, as high-stage disease is
associated with increased symptom experience both before and
after treatment (Routledge et al, 2003).
In this study, QoL and treatment-related toxicity were recorded
simultaneously at pre- and post-treatment time points to assess
changes over time and to determine any relationship between the
two. The EORTC QLQ-C30 questionnaire used in this study was
designed to be applicable to a wide range of cancer patients as a
core questionnaire. There is now a specific cervical cancer module
(EORTC QLQ-CX24) to assess QoL in patients with cervical cancer
and an endometrial cancer module under development. These
disease-specific measures have been shown to improve on the
generic EORTC QLQ-C30 questionnaire and to provide a better
assessment of the issues that affect the QoL of women treated
exclusively for gynaecological cancers (Greimel et al, 2006). This
study was initiated in 1998, however, before the introduction of the
EORTC QLQ-CX24 in 2006. Hence, the core EORTC QLQ-C30
questionnaire was used here. In addition, the use of the LENT
SOMA questionnaire to record treatment-related morbidity may
be criticised as the system is not in widespread use. However, the
items used in the questionnaire have been incorporated into the
observer-based CTCAE toxicity scoring system, which has been
proposed as the new standard for reporting adverse events in
clinical trials (Chen et al, 2006).
Missing questionnaires are a frequent problem in QoL studies
and may produce biased results. For this study the overall level of
compliance was 72.2%, which is comparable with published
reports for compliance rates in other prospective QoL studies
(Kaasa et al, 1998). Finally all patients who experienced disease
recurrence or progression of disease were excluded from this
study, and, as such, our results may only be applicable to
gynaecological patients with a generally ‘good’ physical condition
and positive prognostic factors.
In conclusion, this study has shown that radical radiotherapy
has a negative effect on QoL in gynaecological cancer patients.
These effects are most apparent immediately after treatment. High
treatment morbidity scores are associated with lower global QoL.
Simultaneous use of both a QoL measure and a toxicity scoring
system should be implemented in oncology trials and longitudinal
studies. This will enable us in the future to identify the symptoms
that cause the greatest distress to patients and have the biggest
effect on QoL scores. In turn this will lead to effective management
strategies that can be implemented to reduce the experience of
these late treatment effects; therefore improving the QoL in
gynaecological cancer patients treated with radiotherapy.
45
50
55
60
65
70
75
80
Low LENT SOMA score
High LENT SOMA score
Pre
Post
6 weeks
12 months
Good
Poor
36 months 24 months
Figure 3 European Organisation for the Research and Treatment of
Cancer QLQ-C30 global quality of life subscale over time for the ‘high’ and
‘low’ Late Effects Normal Tissues – Subjective Objective Management
Analysis (LENT SOMA) score groups.
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